Article | Published:

ASPM promotes prostate cancer stemness and progression by augmenting Wnt−Dvl-3−β-catenin signaling

Oncogenevolume 38pages13401353 (2019) | Download Citation

  • A Correction to this article was published on 02 November 2018


Recurrent and hormone-refractory prostate cancer (PCA) exhibits aggressive behaviors while current therapeutic approaches show little effect of prolonging the survival of patients with PCA. Thus, a deeper understanding of the patho-molecular mechanisms underlying the disease progression in PCA is crucial to identify novel diagnostic and/or therapeutic targets to improve the outcome of patients. Recent evidence suggests that activation of Wnt signaling in cancer stem cells (CSCs) contributes to cancer progression in malignant tumors. Here, we report that a novel Wnt co-activator ASPM (abnormal spindle-like microcephaly associated) maintains the prostate CSC subpopulation by augmenting the Wnt-β-catenin signaling in PCA. ASPM expression is incrementally upregulated in primary and metastatic PCA, implicating its potential role in PCA progression. Consistently, downregulation of ASPM expression pronouncedly attenuated the proliferation, colony formation, and the invasive behavior of PCA cells, and dramatically reduced the number of ALDH+ CSCs and inhibited cancer stemness and tumorigenicity. Mechanistically, ASPM interacts with disheveled-3 (Dvl-3), a cardinal upstream regulator of canonical Wnt signaling, and inhibits its proteasome-dependent degradation, thereby increasing its protein stability and enabling the Wnt-induced β-catenin transcriptional activity in PCA cells. In keeping with the role of ASPM as a CSC-regulator, ASPM co-localizes with ALDH in PCA tissues and its expression exhibits high intra-tumoral heterogeneity. The proportion of high-ASPM-expressing cells in the tumor inversely correlates with the relapse-free survival of PCA patients. Collectively, our data points to ASPM as a novel oncoprotein and an essential regulator of Wnt signaling and cancer stemness in PCA, which has important clinical and therapeutic significance.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 02 November 2018

    In the published version of this paper the author Shu-Pin Huang’s surname was incorrectly given as Hwang instead of Huang. This has now been corrected in the HTML and PDF versions of the paper.


  1. 1.

    Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–84.

  2. 2.

    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–7.

  3. 3.

    Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastas- Rev. 2001;20:333–49.

  4. 4.

    Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52:154–79.

  5. 5.

    Gilligan T, Kantoff PW. Chemotherapy for prostate cancer. Urology. 2002;60:94–100.

  6. 6.

    Kouprina N, Pavlicek A, Collins NK, Nakano M, Noskov VN, Ohzeki J, et al. The microcephaly ASPM gene is expressed in proliferating tissues and encodes for a mitotic spindle protein. Hum Mol Genet. 2005;14:2155–65.

  7. 7.

    Bruning-Richardson A, Bond J, Alsiary R, Richardson J, Cairns DA, McCormack L, et al. ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. Br J Cancer. 2011;104:1602–10.

  8. 8.

    van der Voet M, Berends CW, Perreault A, Nguyen-Ngoc T, Gonczy P, Vidal M, et al. NuMA-related LIN-5, ASPM-1, calmodulin and dynein promote meiotic spindle rotation independently of cortical LIN-5/GPR/Galpha. Nat Cell Biol. 2009;11:269–77.

  9. 9.

    Fish JL, Kosodo Y, Enard W, Paabo S, Huttner WB. Aspm specifically maintains symmetric proliferative divisions of neuroepithelial cells. Proc Natl Acad Sci USA. 2006;103:10438–43.

  10. 10.

    Capecchi MR, Pozner A. ASPM regulates symmetric stem cell division by tuning Cyclin E ubiquitination. Nat Commun. 2015;6:8763.

  11. 11.

    Jiang K, Rezabkova L, Hua S, Liu Q, Capitani G, Altelaar AFM, et al. Microtubule minus-end regulation at spindle poles by an ASPM-katanin complex. Nat Cell Biol. 2017;19:480–92.

  12. 12.

    Bikeye SN, Colin C, Marie Y, Vampouille R, Ravassard P, Rousseau A, et al. ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. Cancer Cell Int. 2010;10:1.

  13. 13.

    Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, et al. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 2008;14:4814–20.

  14. 14.

    Xie JJ, Zhuo YJ, Zheng Y, Mo RJ, Liu ZZ, Li BW, et al. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer. Int Urol Nephrol. 2017;49:817–23.

  15. 15.

    Vange P, Bruland T, Beisvag V, Erlandsen SE, Flatberg A, Doseth B, et al. Genome-wide analysis of the oxyntic proliferative isthmus zone reveals ASPM as a possible gastric stem/progenitor cell marker over-expressed in cancer. J Pathol. 2015;237:447–59.

  16. 16.

    Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, et al. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression. Gastroenterology. 2013;145:1110–20.

  17. 17.

    Major MB, Roberts BS, Berndt JD, Marine S, Anastas J, Chung N, et al. New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening. Sci Signal. 2008;1:ra12.

  18. 18.

    Buchman JJ, Durak O, Tsai LH. ASPM regulates Wnt signaling pathway activity in the developing brain. Genes Dev. 2011;25:1909–14.

  19. 19.

    Yokoyama NN, Shao S, Hoang BH, Mercola D, Zi X. Wnt signaling in castration-resistant prostate cancer: implications for therapy. Am J Clin Exp Urol. 2014;2:27–44.

  20. 20.

    Schneider JA, Logan SK.Revisiting the role of Wnt/beta-catenin signaling in prostate cancer.Mol Cell Endocrinol. 2018;462(Pt A):3–8.

  21. 21.

    Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009;19:683–97.

  22. 22.

    van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res. 2010;70:5163–73.

  23. 23.

    Liu C, Liu R, Zhang D, Deng Q, Liu B, Chao HP, et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun. 2017;8:14270.

  24. 24.

    Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004;117:3539–45.

  25. 25.

    Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. Lab Invest. 2010;90:234–44.

  26. 26.

    Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192–205.

  27. 27.

    Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68.

  28. 28.

    Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–50.

  29. 29.

    Thomsen MK, Ambroisine L, Wynn S, Cheah KS, Foster CS, Fisher G, et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 2010;70:979–87.

  30. 30.

    Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res. 2007;67:528–36.

  31. 31.

    Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, et al. SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest. 2016;126:1745–58.

  32. 32.

    Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, et al. Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis. Cancer Res. 2017;77:1331–44.

  33. 33.

    Gao C, Chen YG. Dishevelled: The hub of Wnt signaling. Cell Signal. 2010;22:717–27.

  34. 34.

    Angers S, Thorpe CJ, Biechele TL, Goldenberg SJ, Zheng N, MacCoss MJ, et al. The KLHL12-Cullin-3 ubiquitin ligase negatively regulates the Wnt-beta-catenin pathway by targeting Dishevelled for degradation. Nat Cell Biol. 2006;8:348–57.

  35. 35.

    Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012;481:85–9.

  36. 36.

    Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12:468–76.

  37. 37.

    Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17:867–74.

  38. 38.

    Gray RS, Roszko I, Solnica-Krezel L. Planar cell polarity: coordinating morphogenetic cell behaviors with embryonic polarity. Dev Cell. 2011;21:120–33.

  39. 39.

    Strutt DI, Weber U, Mlodzik M. The role of RhoA in tissue polarity and Frizzled signalling. Nature. 1997;387:292–5.

  40. 40.

    Narimatsu M, Bose R, Pye M, Zhang L, Miller B, Ching P, et al. Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell. 2009;137:295–307.

  41. 41.

    Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151:1542–56.

  42. 42.

    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–8.

  43. 43.

    Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–7.

  44. 44.

    Arensman MD, Kovochich AN, Kulikauskas RM, Lay AR, Yang PT, Li X, et al. WNT7B mediates autocrine Wnt/beta-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma. Oncogene. 2014;33:899–908.

  45. 45.

    Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986;46:5419–25.

  46. 46.

    Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5.

  47. 47.

    Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–243.

  48. 48.

    Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, et al.Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic proces.BMC Cancer. 2007;7:64

  49. 49.

    Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al.Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005;8:393–406.

Download references


Supported in part by Ministry of Science and Technology grants MOST 104-2314-B-400-022, MOST 105-2314-B-400-018 (KKT), MOST 105-2314-B-400-003 (L-TC), Taipei Medical University grant DP2-107-21121-C-04 (KKT), Ministry of Health and Welfare grant MOHW107-TDU-B-212-114020 (KKT) and National Health Research Institutes intramural grant CA-106-PP-09 (KKT).

Author information

Author notes

  1. These authors contributed equally: Vincent C. Pai, Chung-Chi Hsu.


  1. Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City, 11031, Taiwan

    • Vincent C. Pai
    • , Chung-Chi Hsu
    • , Tze-Sian Chan
    •  & Kelvin K. Tsai
  2. Division of Gastroenterology, Department of Internal Medicine, Laboratory of Advanced Molecular Therapeutics, Wan Fang Hospital, Taipei Medical University, Taipei City, 11696, Taiwan

    • Chung-Chi Hsu
    • , Tze-Sian Chan
    •  & Kelvin K. Tsai
  3. National Institute of Cancer Research, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan

    • Vincent C. Pai
    • , Wen-Ying Liao
    • , Li-Tzong Chen
    •  & Kelvin K. Tsai
  4. Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan

    • Chih-Pin Chuu
    •  & Ching-Yu Lin
  5. Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei City, 11696, Taiwan

    • Wei-Yu Chen
  6. Department of Teaching and Research, Taichung Hospital, Ministry of Health and Welfare, Taichung City, 40343, Taiwan

    • Chi-Rong Li
  7. Department of Urology, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, 80756, Taiwan

    • Shu-Pin Huang


  1. Search for Vincent C. Pai in:

  2. Search for Chung-Chi Hsu in:

  3. Search for Tze-Sian Chan in:

  4. Search for Wen-Ying Liao in:

  5. Search for Chih-Pin Chuu in:

  6. Search for Wei-Yu Chen in:

  7. Search for Chi-Rong Li in:

  8. Search for Ching-Yu Lin in:

  9. Search for Shu-Pin Huang in:

  10. Search for Li-Tzong Chen in:

  11. Search for Kelvin K. Tsai in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Kelvin K. Tsai.

Electronic supplementary material

About this article

Publication history





Issue Date